ST
ALNY icon

Spot Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History

Spot Trading’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$2.14M Buy
18,200
+8,600
+90% +$734K 0.04% 697
2017
Q2 		$766K Buy
9,600
+5,000
+109% +$320K 0.02% 1279
2017
Q1 		$236K Buy
+4,600
New +$213K 0.01% 1809
2016
Q3 		– Sell
-400
Closed -$22K – 3026
2016
Q2 		$22K Buy
+400
New +$25.2K ﹤0.01% 2964
2014
Q4 		– Sell
-100
Closed -$8K – 3972
2014
Q3 		$8K Sell
100
-5,500
-98% -$355K ﹤0.01% 4073
2014
Q2 		$354K Sell
5,600
-92,000
-94% -$5.47M ﹤0.01% 2947
2014
Q1 		$6.55M Buy
97,600
+78,300
+406% +$6.06M 0.04% 682
2013
Q4 		$1.24M Buy
19,300
+18,800
+3,760% +$1.12M 0.01% 1822
2013
Q3 		$32K Sell
500
-162,900
-100% -$8.12M ﹤0.01% 3685
2013
Q2 		$5.07M Buy
+163,400
New +$4.35M 0.03% 709

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Spot Trading's ALNY Position: Q3 2017 in Review

Spot Trading sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 329 shares — an estimated $28.1K sold.

Spot Trading first reported a position in ALNY in Q2 2013 and held it in 5 quarters. The position peaked at $601K in Q3 2014. 236 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

  • Spot Trading reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Spot Trading sold 329 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $28.1K.
  • Spot Trading first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Spot Trading's Alnylam Pharmaceuticals position peaked at $601K in Q3 2014.
  • 236 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.